Today: October 7, 2015, 5:44 pm

Key Panel discussion at 3rd Oncology Partnering Conf. – July 7-8, 2014, Boston

Key Panel discussion at 3rd Oncology Partnering Conf. – July 7-8, 2014, Boston 2014-04-05 08:49:09
Panel Discussion on “Innovative Partnering & Deal-making” Features Executives from Sanofi, Merck Serono, Johnson & Johnson, Novartis, AnaptysBio, and MedImmune at the 3rd Oncology Partnering & Deal-Making Conference (July 7-8, 2014 in Boston, MA)

This panel discussion will cover topics including rationale-driving key deals of 2013 and continued trends into 2014 as well as aligning deal structures with corporate strategic goals and how the heightened risk environment is affecting deals. The pros and cons of regional deal-making will also be discussed. There are key questions to innovative partnering – at what stage or what type of data makes the asset most attractive to a buyer? How do you find and decide who a good partner is and what determines the value of the deal? What preparations should you make before the deal and what kind of terms besides the financials should you take into consideration? And perhaps most importantly, what are the criteria to attract investors? Come join this important and timely discussion.

Panel participants will include Anne Altmeyer, Vice President of Business Development and Licensing at Novartis; Varavani Dwarki, Vice President and Worldwide Head of Alliance Management Oncology and NCI Liaison at Sanofi; Catherine-Anne Pickering, Head of Oncology Licensing and Global Business Development at Merck Serono; Shakti Narayan, Senior Director of Transactions at Johnson & Johnson Innovation Center; Reginald Seeto, Head of Partnering and Strategy at MedImmune; Hamza Suria, President and Chief Executive Officer of AnaptysBio

GTCBio’s 3rd Oncology Partnering & Deal Making Conference is a partnership and business development conference that provides an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations and learn about relevant issues in oncology that will affect the pharmaceutical industry. Experts in the field of oncology will present on the latest discoveries, novel technologies, business development trends, markets, partnership opportunities, alliance management, value maximization vs. capital efficiency, and the rebirth of IPOs. There will be a mix of presentations and interactive panel discussions so join your business development colleagues at this unique partnering forum!

This conference is part of the larger Novel Cancer Therapeutics Summit, which consist of two co-located parallel conferences:
3rd Oncology Partnering & Deal-making Conference
5th Cancer Targets & Therapeutics Conference

For more information, please visit

Press Information
635 W. Foothill Blvd. Monrovia, CA 91016

Kristen Starkey


Published by
Rania hafez

# 381 Words
Related Articles
More From Science
The US Air Force (AFRL/RXC) has awarded UES Inc. (UES) a $32.3 million, indefinite-delivery/indefinite-quantity contract under [..]
AFRL Selects UES to Develop Human Performance [..]
UES Inc., a Dayton-based Science and Technology firm and 2015 R&D100 Award Finalist, announced that the US Air Force (AFRL/RQK) [..]
Historic space artefact found on eBay - [..]
In 1969 Neil Armstrong and Buzz Aldrin became the first men to walk on the moon. Sadly their historic boots [..]
UES Hosts Successful Inaugural Robo-Met.3D® User Conference
Dayton, OH, 17th September 2015 UES Inc., a Dayton-based Science and Technology firm and 2015 R&D100 Award Finalist, hosted a [..]
UES Previews Fast, Accurate Technology to Detect [..]
UES’ SilverHAWQ® technology development team had the honor of presenting to a select group from the Ohio House of Representatives [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.